K 001
Alternative Names: K-001; Peptidoglycan complex of spirulinaLatest Information Update: 22 Apr 2022
Price :
$50 *
At a glance
- Originator Hwealth Pharmaceutical; Shanghai Jiaotong University School of Medicine
- Developer Shanghai Jiaotong University School of Medicine
- Class Amino acids; Antineoplastics; Polysaccharides
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II/III Pancreatic cancer
Most Recent Events
- 22 Apr 2022 Phase II/III development is ongoing in Pancreatic cancer in China (NCT04183478) (ChiCTR-IIR-17013424)
- 29 May 2020 Efficacy and adverse events data from a phase I trial in Pancreatic cancer presented at the 56th Annual Meeting of the American Society of Clinical Oncology (ASCO-2020)
- 03 Dec 2019 Clinical development for Pancreatic cancer is still ongoing China (NCT04183478)